-
Research Services<a class="dhimg1" href="/shichangdetail1/9.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/8926ff01-64bc-4928-a995-396bdb9d8102.jpg" alt="Aniphe BioLab"> </a> <a class="dhimg2" href="/shichangdetail/8.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/26342b34-4f1e-4d28-9166-7b685e6d70c3.jpg" alt="Aniphe BioLab"> </a>
-
-
Preclinical CRO<a class="dhimg1" href="/shichangdetail/6.html" target="_self" rel="nofollow"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/cc43bac1-07d9-4340-9677-fbe01c51330a.jpg" alt="Aniphe BioLab"> </a> <a class="dhimg2" href="/shichangdetail/10.html" rel="nofollow" target="_self"> <img src="https://omo-oss-image.thefastimg.com/portal-saas/pg2026042316544414203/cms/image/f1d8f739-0d36-4cb8-adeb-26de791d909c.jpg" alt="Aniphe BioLab"> </a>
-
-
-
-
Publish an article
Glomerular disease
Introduction to Animal Models of Glomerular Diseases
Glomerular disease is a group of renal disorders characterized by damage to the glomerular filtration barrier. Clinically, it manifests primarily as proteinuria, hematuria, and abnormal renal function, and constitutes a major cause of chronic kidney disease and end-stage renal disease. Animal models of glomerular disease can reliably recapitulate hallmark pathological features, including podocyte injury, mesangial cell proliferation, inflammatory infiltration, and glomerulosclerosis, thereby providing robust experimental support for elucidating disease pathogenesis, validating key therapeutic targets, and advancing precision medicine and innovative drug development in nephrology.
Service Advantages of the Aniphe BioLab Glomerular Disease Animal Model Platform
The Aniphe BioLab glomerular disease animal model platform offers a wide range of highly stable models and end-to-end supporting services, efficiently underpinning research and development in the field of kidney diseases.
![]() |
A wide variety of models are available. It encompasses mainstream glomerular disease models, with a variety of modeling approaches to meet diverse experimental requirements. |
![]() |
The model quality is excellent. A standardized modeling protocol ensures a high success rate, stable phenotypes, and excellent reproducibility of experimental data. |
![]() |
Solid technical expertise Our expert technical team operates with great proficiency, ensuring short modeling timelines and high animal survival rates. |
![]() |
One-stop service We integrate modeling, animal husbandry, and various assays into a seamless, end-to-end workflow, saving you time and effort. |
![]() |
Flexible and convenient delivery Some models are available for immediate delivery, and custom experimental protocols can be developed upon request. |
|
The filament occlusion method (MCAO) is used to establish the model, which avoids craniotomy, minimizes animal trauma, and yields highly reproducible results. |
Standardized surgical protocols, combined with an experienced technical team, ensure the stability and consistency of model creation. |
The Longa score and the Bederson score, combined with TTC staining, were used to comprehensively validate the model’s phenotype. |
Retain photographs of key procedural milestones and original records to ensure traceability of the experimental process. |
A standardized in vivo solution that meets the needs of cerebral ischemia mechanism research and drug efficacy evaluation. |
| Modeling cycle |
1–2 weeks |
|
|
Mice, rats, rabbits, and miniature pigs |
|
|
Prednisone, cyclophosphamide, benazepril, and losartan are commonly used as positive controls, exerting renal protective effects through anti-inflammatory, immunomodulatory, and proteinuria‑lowering mechanisms. |
|
|
It is primarily used for studying the pathogenic mechanisms of glomerular diseases, screening anti‑proteinuric and renoprotective drugs, evaluating the efficacy of anti‑fibrotic agents in the kidney, and conducting preclinical research on novel therapeutic strategies. |
Construction of Animal Models for Glomerular Diseases
BSA + LPS + carbon tetrachloride–induced model: BSA immunization combined with LPS and carbon tetrachloride administration is used to induce immune‑mediated glomerular injury, reliably reproducing hallmark pathological features such as proteinuria, inflammatory infiltrate, and glomerulosclerosis.
Transgenic mouse models: By employing genetic engineering techniques, glomerular disease models can be established, enabling the simulation of glomerular injury and disease progression resulting from specific genetic abnormalities, thereby providing a reliable platform for investigating pathogenic mechanisms and validating therapeutic targets.
Aniphe BioLab Inc.
Address:
Runcheng, No. 8 Longtai Road, Jiangbei New Area, Nanjing City, Jiangsu Province
Building 8, Science Park
Postal Code: 210007
Phone:025-8520 8061
Email:info@aniphebio.com(Consultation)
Email:order@aniphebio.com(Order)
WeChat Official Account
Video Account
















Positive drug
Application areas
Su Public Security Bureau Internet Information Service Filing No. 32010402001421